Most Read Articles
Pearl Toh, 4 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
24 Mar 2020
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.

Biochemical recurrence-free survival in prostate cancer improves after WPRT

12 Jan 2020

Whole-pelvis radiotherapy (WPRT) improves biochemical recurrence-free survival (bRFS), but not distant metastasis-free survival (DMFS) and prostate cancer-specific survival (PCSS), in patients with Gleason grade group 5 prostate cancer (PCa) treated with either external-beam radiotherapy (EBRT) or EBRT with a brachytherapy boost (EBRT+BT), a recent study has found.

The study included 1,170 eligible PCa patients, of whom 734 (median age, 68 years) received EBRT alone and 436 EBRT+BT (median age, 68 years). Study outcomes were bRFS, DMFS and PCSS, which were compared between groups after propensity score adjustments.

More than half (53 percent; n=619) of the patients received WPRT. Kaplan-Meier curves, adjusted for potential covariates, showed that in the EBRT group, the adjusted 5-year bRFS rates in patient with vs without WPRT were 66 percent and 58 percent, respectively. In the EBRT+BT patients, the corresponding rates were 88 percent and 78 percent.

In the propensity score-adjusted model, WPRT provided a significant benefit in the EBRT+BT patients (hazard ratio [HR], 0.5, 95 percent confidence interval [CI], 0.2–0.9; p=0.02), but not in those who received EBRT alone (p=0.4).

The opposite was true for DMFS, which did not show signs of benefit from WPRT in either the EBRT alone (HR, 1.1, 95 percent CI, 0.7–1.7; p=0.8) or EBRT+BT (HR, 0.6, 95 percent CI, 0.3–1.4; p=0.2) treatment groups.

PCSS, likewise, derived no significant benefit from WPRT (EBRT alone: HR, 0.7, 95 percent CI, 0.4–1.1; p=0.1; EBRT+BT: HR, 0.5, 95 percent CI, 0.2–1.2; p=0.1).

Editor's Recommendations
Most Read Articles
Pearl Toh, 4 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
24 Mar 2020
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.